These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38798243)

  • 41. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting the response to chemotherapy in gastric adenocarcinoma: who benefits from neoadjuvant chemotherapy?
    Robb WB; Mariette C
    Recent Results Cancer Res; 2012; 196():241-68. PubMed ID: 23129379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
    Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
    Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report.
    Lin CY; Mehta P; Waters KM; Chang E; Hendifar A; Osipov A; Burch M; Lin DC; Gangi A; Cho M; Gong J
    AME Case Rep; 2021; 5():30. PubMed ID: 34312609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy.
    Huang L; Chen S; Yang WT; Shao Z
    Oncotarget; 2017 Jun; 8(24):39703-39710. PubMed ID: 28055977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?
    Turgeon MK; Lee RM; Keilson JM; Ju MR; Porembka MR; Alterio RE; Kronenfeld J; Datta J; Goel N; Wang A; Lee AY; Fernandez M; Richter H; Maker AV; Maithel SK; Russell MC
    J Surg Oncol; 2021 Sep; 124(4):551-559. PubMed ID: 34061369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis.
    Xu H; Li T; Shao G; Wang W; He Z; Xu J; Qian Y; Liu H; Ge H; Wang L; Zhang D; Yang L; Li F; Xu Z
    Front Immunol; 2023; 14():1193614. PubMed ID: 37426646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.
    Ganschow P; Hofmann L; Stintzing S; Heinemann V; Angele M; Werner J; Schulz C
    J Gastrointest Surg; 2021 Jan; 25(1):58-66. PubMed ID: 32040809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of neoadjuvant treatment strategy on perioperative outcomes in locally advanced rectal cancer.
    McFeetors C; O'Connell LV; Choy M; Dundon N; Regan M; Joyce M; Meshkat B; Hogan A; Nugent E
    Colorectal Dis; 2024 Apr; 26(4):684-691. PubMed ID: 38424706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
    Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
    Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.
    Monti M; Prochowski Iamurri A; Bianchini D; Gallio C; Esposito L; Montanari D; Ruscelli S; Molinari C; Foca F; Passardi A; Vittimberga G; Morgagni P; Frassineti GL
    Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 56. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
    Woei-A-Jin FJSH; Weijl NI; Burgmans MC; Fariña Sarasqueta A; van Wezel JT; Wasser MNJM; Coenraad MJ; Burggraaf J; Osanto S
    Oncologist; 2021 Oct; 26(10):854-864. PubMed ID: 34251745
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer.
    Lee SM; Kim SH; Lee JM; Im SA; Bang YJ; Kim WH; Kim MA; Yang HK; Lee HJ; Kang WJ; Han JK; Choi BI
    Abdom Imaging; 2009 Jul; 34(4):430-40. PubMed ID: 18546037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept?].
    Gockel I; Lordick F
    Chirurg; 2020 May; 91(5):384-390. PubMed ID: 32112151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Gastric Tumor Perforation with Conservative Treatment during Neoadjuvant Chemotherapy.
    Bozkurt E; Omeroglu S; Capkinoglu E; Guven O; Mihmanli M
    J Coll Physicians Surg Pak; 2022 Jan; 32(1):117-118. PubMed ID: 34983163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.